Patents by Inventor Quynh Nhu NGUYEN

Quynh Nhu NGUYEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINAZOLINE COMPOUNDS AND METHODS OF USE
    Publication number: 20240092761
    Abstract: Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects, the disclosure generally relates to substituted quinolinone amide compounds or salts of Formula (I), (IA), (IAA), (IAAA), (IB), (IBB), (IC), (ICC), (II), or (IIA) and pharmaceutical compositions thereof.
    Type: Application
    Filed: July 18, 2023
    Publication date: March 21, 2024
    Inventors: William VERNIER, Quynh Nhu NGUYEN, Nomaan REZAYEE, Laurent GOMEZ, Chao Zhang, Thomas Francis MILLER, III, Frederick Roy MANBY
  • AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE
    Publication number: 20240034731
    Abstract: Substituted aza-quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects, the disclosure generally relates to substituted quinolinone amide compounds or salts of Formula (I), (IA), (IAA), (IAAA), (IB), (IBB), (IC), (ICC), (ID), (IDD), (IE), and (IEE) and pharmaceutical compositions thereof.
    Type: Application
    Filed: July 24, 2023
    Publication date: February 1, 2024
    Inventors: William VERNIER, Quynh Nhu NGUYEN, Nomaan REZAYEE, Laurent GOMEZ, Chao ZHANG, Thomas Francis MILLER, III, Frederick Roy MANBY
  • Antiangiogenic peptides
    Patent number: 7655626
    Abstract: The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: February 2, 2010
    Assignees: Universite de Liege, Faculte Universitaire des Sciences Agronomiques de Gembloux
    Inventors: Joseph Martial, Ingrid Struman, Ngoc-Quynh-Nhu Nguyen, Robert Brasseur, Laurence Lins
  • Antiangiogenic Peptides
    Publication number: 20080039384
    Abstract: The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp
    Type: Application
    Filed: August 11, 2005
    Publication date: February 14, 2008
    Applicant: UNIVERSITE DE LIEGE
    Inventors: Joseph Martial, Ingrid Struman, Ngoc-Quynh-Nhu Nguyen, Robert Brasseur, Laurence Lins